title: Haemostatic therapy in coronary artery bypass graft patients with decreased platelet function: comparison of fibrinogen concentrate with allogeneic blood products.
abstract: BACKGROUND
  Patients undergoing coronary artery bypass grafting (CABG) are at risk of postoperative bleeding because of decreased platelet function and cardiopulmonary bypass (CPB)-induced haemostatic impairment. Fibrinogen concentration decreases by 34-42% of the preoperative level by the end of CPB. An inverse relationship between perioperative plasma fibrinogen levels and postoperative bleeding has been reported in CABG patients. Administration of fibrinogen concentrate after weaning from CPB in patients with diffuse microvascular bleeding may help promote haemostasis. We compared patient outcomes following fibrinogen concentrate administration or transfusion of allogeneics in CABG patients with decreased platelet function.
  
  
  METHODS
  Thirty-eight patients with decreased preoperative platelet function in Multiplate aggregometry were included. Patients with bleeding after CPB received either fibrinogen concentrate (guided by the measurement of fibrin clot quality using the FIBTEM thromboelastometric test) or allogeneics.
  
  
  RESULTS
  Twenty-nine of 38 patients received haemostatic therapy (bleeding + fibrinogen group, n = 10; bleeding + allogeneics group, n = 19). Total transfusion (median (interquartile range)) was significantly lower in the bleeding + fibrinogen group (0 (0, 3.8) units), compared with the bleeding + allogeneics group (6 (5, 8) units, p = 0.0073). Bolus administration of fibrinogen concentrate increased FIBTEM maximum clot firmness from 10.5 (9.3, 11) mm after CPB to 20.5 (20, 21.8) mm at the end of surgery. Postoperative outcomes were similar in both groups. No treatment-related complications were observed after fibrinogen concentrate.
  
  
  CONCLUSIONS
  In CABG patients with bleeding after CPB, FIBTEM-guided administration of fibrinogen concentrate resulted in overall decreased transfusion, compared with haemostatic therapy with allogeneics. Fibrinogen concentrate administration increased the fibrin clot quality and helped achieve haemostasis.
authors.affiliation: Department of Anaesthesiology and Intensive Care Medicine, SALK University Hospital, Salzburg, Austria. solomon.cristina@googlemail.com
authors.forename: Cristina
authors.initials: C
authors.lastname: Solomon
authors.forename: Herbert
authors.initials: H
authors.lastname: Schöchl
authors.forename: Alexander
authors.initials: A
authors.lastname: Hanke
authors.forename: Andreas
authors.initials: A
authors.lastname: Calatzis
authors.forename: Christian
authors.initials: C
authors.lastname: Hagl
authors.forename: Kenichi
authors.initials: K
authors.lastname: Tanaka
authors.forename: Niels
authors.initials: N
authors.lastname: Rahe-Meyer
mesh_terms: D000368:Aged; D001792:Blood Platelets / Q000502:physiology*; D001803:Blood Transfusion; D001026:Coronary Artery Bypass; D005260:Female; D005340:Fibrinogen / Q000378:metabolism*; D006487:Hemostasis; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D005340:Fibrinogen